Literature DB >> 16440135

Anakinra in mutation-negative CINCA syndrome.

José Luis Callejas1, Javier Oliver, Javier Martín, Norberto Ortego.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16440135     DOI： 10.1007/s10067-005-0168-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  10 in total

1.  Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome.

Authors:  B Granel; J Serratrice; P Disdier; P-J Weiller
Journal:  Rheumatology (Oxford)       Date:  2005-01-25       Impact factor: 7.580

2.  Positive clinical and biochemical responses to anakinra in a 3-yr-old patient with cryopyrin-associated periodic syndrome (CAPS).

Authors:  E Ramos; J I Aróstegui; S Campuzano; J Rius; C Bousoño; J Yagüe
Journal:  Rheumatology (Oxford)       Date:  2005-04-19       Impact factor: 7.580

3.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.

Authors:  C H Hannum; C J Wilcox; W P Arend; F G Joslin; D J Dripps; P L Heimdal; L G Armes; A Sommer; S P Eisenberg; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

4.  Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome.

Authors:  H M Hoffman; J L Mueller; D H Broide; A A Wanderer; R D Kolodner
Journal:  Nat Genet       Date:  2001-11       Impact factor: 38.330

5.  The CINCA syndrome: a rare cause of chronic arthritis and multisystem inflammatory disorders.

Authors:  H de Boeck; T Scheerlinck; J Otten
Journal:  Acta Orthop Belg       Date:  2000-12       Impact factor: 0.500

6.  Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes.

Authors:  Jérôme Feldmann; Anne-Marie Prieur; Pierre Quartier; Patrick Berquin; Stephanie Certain; Elisabetta Cortis; Dominique Teillac-Hamel; Alain Fischer; Genevieve de Saint Basile
Journal:  Am J Hum Genet       Date:  2002-05-24       Impact factor: 11.025

7.  Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel.

Authors:  Joost Frenkel; Nico M Wulffraat; Wietse Kuis
Journal:  Arthritis Rheum       Date:  2004-11

8.  Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.

Authors:  Philip N Hawkins; Helen J Lachmann; Ebun Aganna; Michael F McDermott
Journal:  Arthritis Rheum       Date:  2004-02

9.  A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients.

Authors:  A M Prieur; C Griscelli; F Lampert; H Truckenbrodt; M A Guggenheim; D J Lovell; P Pelkonnen; J Chevrant-Breton; B M Ansell
Journal:  Scand J Rheumatol Suppl       Date:  1987

Review 10.  NALPs: a novel protein family involved in inflammation.

Authors:  Jürg Tschopp; Fabio Martinon; Kimberly Burns
Journal:  Nat Rev Mol Cell Biol       Date:  2003-02       Impact factor: 94.444
  10 in total
  1 in total

1.  Extreme efficiency of anti-interleukin 1 agent (anakinra) in a Japanese case of CINCA syndrome.

Authors:  Yasuyo Kashiwagi; Hisashi Kawashima; Shigeo Nishimata; Ryuhei Nagao; Kiyoko Watanabe; Kouji Takekuma; Akinori Hoshika
Journal:  Clin Rheumatol       Date:  2007-09-22       Impact factor: 2.980
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.